Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Fujifilm Initiates PI Study of MDS Treatment FF-10501 in Japan
June 4, 2013
- AZ to Assess Possibility of EGFR Mutation Testing via Blood in Japan-Europe Study
June 3, 2013
- Four Pharmas Launch Filgrastim, Third Biosimilars in Japan
June 3, 2013
- EvaluatePharma Estimates Orphan Drug Market Will Grow to US$127 Billion by 2018
May 31, 2013
- Kyowa Kirin Launches Parkinson’s Disease Treatment Nouriast in Japan
May 31, 2013
- Sawai Aims for All Its New MRs to Pass MR Examination for Fifth Year in a Row
May 31, 2013
- Astellas, Amgen Clinch Strategic Alliance on 5 Products; JV to Begin Operations in October
May 30, 2013
- Eisai Launches Antiepileptic Treatment Inovelon
May 30, 2013
- Nippon Shinyaku Launches Regtect for Supporting Maintenance of Abstinence in Alcohol-Dependent Patients
May 30, 2013
- Ex-Novartis Employee Attended Key Panel Meetings for Diovan Trial
May 29, 2013
- MTPC Files NDA for SGLT-2 Inhibitor Canagliflozin in Japan
May 29, 2013
- Sales of 27 JPMA Member Companies Up 2.6%, First Rise in Two Years Thanks to Overseas Sales Growth
May 28, 2013
- Kyorin Aims for Pentasa Sales Increase in FY2013 with Suppository Formulation: President Yamashita
May 28, 2013
- NPhA Member Companies Will Strive to Reach Price Agreements with Wholesalers by September: Chairman Nakamura
May 28, 2013
- Hisamitsu, Asahi Kasei to Launch Overactive Bladder Treatment Neoxy Tape in June
May 28, 2013
- Astellas Files NDA for Prostate Cancer Treatment Enzalutamide in Japan
May 28, 2013
- “No Indication” of Data Manipulation in Diovan Studies: Novartis
May 27, 2013
- Bayer Launches Anticancer Treatment Stivarga
May 27, 2013
- 2012 Earnings: Foreign Pharmas’ Japan Units Underperform Market Growth, Operating Profit Down 21%
May 27, 2013
- Kyowa Kirin to Launch DPP-4 Inhibitor Onglyza in July Without Concurrent Use Restrictions
May 27, 2013
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…